![](https://www.dovepress.com/assets/img/addon/og_logo.png)
Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity
Introduction Since the approval of Taxol® (the first generation paclitaxel formulation) by the FDA in 1992 for treating advanced ovarian cancer, the clinical limitations of this drug have become progressively evident.1 Aiming to solve paclitaxel’s low …